Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devico

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
AIDS (London, England)|June 5, 2007
CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1Alonso Heredia, Bruce Gilliam, Anthony DeVico, et al.
Biochemistry|March 5, 1991
Mode of action of 5'-linked cholesteryl phosphorothioate oligodeoxynucleotides in inhibiting syncytia formation and infection by HIV-1 and HIV-2 in vitroC A Stein, R Pal, A L DeVico, et al.
Science (New York, N.Y.)|March 14, 1986
Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAVF di Marzo Veronese, T D Copeland, A L DeVico, et al.
Molecular Pharmaceutics|March 3, 2025
Investigating the Interaction between Excipients and Monoclonal Antibodies PGT121 and N49P9.6-FR-LS: A Comprehensive AnalysisXun Li, Asuka A Orr, Mohammad M Sajadi, et al.
AIDS (London, England)|September 22, 2007
Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatmentBruce L Gilliam, Alonso Heredia, Anthony Devico, et al.
Structure (London, England : 1993)|March 27, 2020
Antigen-Induced Allosteric Changes in a Human IgG1 Fc Increase Low-Affinity Fcγ Receptor BindingChiara Orlandi, Daniel Deredge, Krishanu Ray, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 25, 2007
Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogensAnthony DeVico, Timothy Fouts, George K Lewis, et al.
Vaccine|June 14, 2003
Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxinK C Bagley, M T Shata, D Y Onyabe, et al.
FEMS Immunology and Medical Microbiology|July 2, 2003
Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1T R Fouts, A L DeVico, D Y Onyabe, et al.
Antimicrobial Agents and Chemotherapy|May 9, 2007
Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitroAlonso Heredia, Bruce Gilliam, Olga Latinovic, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
AIDS (London, England)|June 5, 2007
CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1Alonso Heredia, Bruce Gilliam, Anthony DeVico, et al.
Biochemistry|March 5, 1991
Mode of action of 5'-linked cholesteryl phosphorothioate oligodeoxynucleotides in inhibiting syncytia formation and infection by HIV-1 and HIV-2 in vitroC A Stein, R Pal, A L DeVico, et al.
Science (New York, N.Y.)|March 14, 1986
Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAVF di Marzo Veronese, T D Copeland, A L DeVico, et al.
Molecular Pharmaceutics|March 3, 2025
Investigating the Interaction between Excipients and Monoclonal Antibodies PGT121 and N49P9.6-FR-LS: A Comprehensive AnalysisXun Li, Asuka A Orr, Mohammad M Sajadi, et al.
AIDS (London, England)|September 22, 2007
Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatmentBruce L Gilliam, Alonso Heredia, Anthony Devico, et al.
Structure (London, England : 1993)|March 27, 2020
Antigen-Induced Allosteric Changes in a Human IgG1 Fc Increase Low-Affinity Fcγ Receptor BindingChiara Orlandi, Daniel Deredge, Krishanu Ray, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 25, 2007
Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogensAnthony DeVico, Timothy Fouts, George K Lewis, et al.
Vaccine|June 14, 2003
Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxinK C Bagley, M T Shata, D Y Onyabe, et al.
FEMS Immunology and Medical Microbiology|July 2, 2003
Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1T R Fouts, A L DeVico, D Y Onyabe, et al.
Antimicrobial Agents and Chemotherapy|May 9, 2007
Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitroAlonso Heredia, Bruce Gilliam, Olga Latinovic, et al.
Pageof 13